The ColdAI Times · Health & Longevity
Technology · World affairs · Business · Science
Medical research, public health, ageing, and the science of longevity.
Novo's 10,052-person preprint and Lilly's 71-person substudy point to slower biological aging on semaglutide and tirzepatide, yet neither has cleared peer review and weight loss may explain the effect.
The oral BTK inhibitor wins a second US indication on a phase 3 cohort in which 29.3% of treated patients, versus 14.0% on placebo, cleared their hives at week 12.
The 2026 prize honors Deisseroth, Hegemann and Nagel for light-gated ion channels, a peer-reviewed research tool whose medical uses, including vision restoration, are still investigational.
Researchers propose 12 biological indicators that may reveal whether an intervention slows aging years before lifespan studies can finish.
A killifish study suggests cGAS can amplify tissue damage in DNA-repair disorders, opening a cautious path toward precision therapies for premature aging.
A UCSF-led brain-computer interface lets people with paralysis control speech and gestures together, pointing toward more natural digital communication.
A 1,785-person study reports a promising blood test for early pancreatic cancer, but prospective screening trials will determine whether it changes care.
A new $125 million grant program targets the data bottleneck in drug discovery, cancer vaccines and public-health research.
A new report credits federal science with major gains against cancer while warning that unstable funding could slow the next wave of breakthroughs.
A late-life study found semaglutide extended female mice’s lives and preserved function, but human longevity claims remain far beyond the evidence.
An experimental collagen-targeted contrast agent found tiny tumors and metastases in animals, but human trials will decide whether the promise survives.